Given the role of the Nrf2-ALDH2/PolG2 pathway in the progression of AML, inhibition of this pathway may prevent disease relapse/resistance and promote sensitisation to chemotherapy. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.